Surgical Science Sweden AB

SUSRF · NASDAQ

$5.48+$5.48 (+0.00%)TodayMarket closed ·
No price history for this range.

About SUSRF

Surgical Science Sweden AB engages in the development of simulators for laparoscopic medical training. The company is headquartered in Goeteborg, Vastra Gotalands and currently employs 313 full-time employees. The company went IPO on 2017-06-19. The systems comprise LapSim, EndoSim and TeamSim trainings. Each training combine graphics and cognitive instruction, imply navigation on touch screens and feature tactile feedback technology. The LapSim trainings consist of laparoscopic exercises that range from basic navigation to advanced suturing, the EndoSim endoscopic exercises range from functions of the scope handle and tube, to loop reduction. The TeamSim comprises procedure modules to train in a real world operation room environment and helps to build team communication skills in crisis and routine situations. The training systems are used by medical training centers and institutes worldwide for practice, validation and certification of students, surgeons, and medical doctors.

Employees
313
Headquarters
Goeteborg, Vastra Gotalands
Listed
Jun 19, 2017
Sector
Health Care
Industry
Health Care Equipment & Supplies

SUSRF key statistics

Market cap
2.80B
Price-earnings ratio
30.11
Dividend yield
—
Average volume
115.25K
Volume
150
Open price
$5.48
High today
$5.48
Low today
$5.48
52 Week high
$94.40
52 Week low
$23.70

Surgical Science Sweden AB (SUSRF) at a glance

Surgical Science Sweden AB (SUSRF) last traded at $5.48, with a market cap of 2.80B and a price-to-earnings ratio of 30.11.

Volume so far is 150 shares, below the average of 115.25K shares a day.

Over the past year Surgical Science Sweden AB has ranged from $23.70 to $94.40, and now sits -26% of the way up that range.

Surgical Science Sweden AB met or beat analyst EPS estimates in 3 of the last 8 quarters. In Q2 FY26 it reported $0.41 per share against an estimate of $0.5555.

SUSRF earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 3 of the last 8 quarters, by 15.2% on average.

  1. Q3 FY24: reported $0.84 per share against an estimate of $0.7196
  2. Q4 FY24: reported $0.71 per share against an estimate of $1.00
  3. Q1 FY25: reported $0.65 per share against an estimate of $0.5303
  4. Q2 FY25: reported -$0.39 per share against an estimate of $0.7137
  5. Q3 FY25: reported $0.40 per share against an estimate of $0.8282
  6. Q4 FY25: reported $0.65 per share against an estimate of $0.7238
  7. Q1 FY26: reported $0.37 per share against an estimate of $0.3485
  8. Q2 FY26: reported $0.41 per share against an estimate of $0.5555

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.